Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Blood (2025) 146 (Supplement 1): 135.

https://doi.org/10.1182/blood-2025-135

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Journal Articles

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Blood (2025) 146 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2025-2238

Published: 2025

Journal Articles

Hematobot: Retrieval‑augmented large language model‑based assistants for therapy, toxicity and frailty management in multiple myeloma by the spanish society of hematology and hemotherapy (SEHH)

Marta Sonia Gonzalez Perez, Adrian Mosquera, Borja Puertas, Rafael Alonso, Esther González García, Maria Casanova Espinosa, Nuria Valdés, Myriam Rodríguez Couso, Carlos Pérez Míguez, Jesús Gómez Fernández, Davide Crucitti, Santiago Bonay, Ignacio Borrajo, Carlos Suárez, María-Victoria Mateos

Blood (2025) 146 (Supplement 1): 6115.

https://doi.org/10.1182/blood-2025-6115

Published: 2025

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Multiple Myeloma Diagnosis and Monitoring

Carlos Pérez Míguez, Jose Angel Diaz Arias, Davide Crucitti, Jesús Gómez Fernández, Manuel Piñeiro Fiel, Marta Sonia Gonzalez Perez, Maria-Victoria Mateos, Adrian Mosquera Orgueira

Blood (2024) 144 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2024-194599

Published: 2024

Journal Articles

Myeloma and Lymphoma Medical Helpers: AI-Powered Decision Support Tools for Hematologic Malignancies

Davide Crucitti, Carlos Pérez Míguez, Marta Sonia Gonzalez Perez, Jose Angel Diaz Arias, Jesús Gómez Fernández, Manuel Piñeiro Fiel, Carlos Panizo, Maria-Victoria Mateos, Adrian Mosquera Orgueira

Blood (2024) 144 (Supplement 1): 7478.

https://doi.org/10.1182/blood-2024-194597

Published: 2024

Journal Articles

Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform

Blood (2024) 144 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2024-201448

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood (2024) 143 (7): 597–603.

https://doi.org/10.1182/blood.2023022083

Published: 2024

Includes: Supplemental data

Journal Articles

Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 871.

https://doi.org/10.1182/blood-2023-185661

Published: 2023

Journal Articles

Epigenetic Profiling and Machine Learning for Enhanced Risk Stratification in Pediatric Acute Lymphoblastic Leukemia

Adrian Mosquera Orgueira, Olga Krali, Andres Peleteiro Raindo, Jose Angel Diaz Arias, Marta Sonia Gonzalez Perez, Manuel Perez Encinas, Manuel Fernandez Sanmartin, Natalia Alonso Vence, Daniel Sinnett, Mats Heyman, Gudmar Lönnerholm, Ulrika Norén-Nyström, Kjeld Schmiegelow, Jessica Nordlund

Blood (2023) 142 (Supplement 1): 4353.

https://doi.org/10.1182/blood-2023-179156

Published: 2023

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Blood (2023) 142 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2023-181235

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM)

Blood (2023) 142 (Supplement 1): 533.

https://doi.org/10.1182/blood-2023-185737

Published: 2023

Journal Articles

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)

Blood (2022) 140 (Supplement 1): 246–248.

https://doi.org/10.1182/blood-2022-165402

Published: 2022

Journal Articles

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Blood (2022) 140 (Supplement 1): 7286–7288.

https://doi.org/10.1182/blood-2022-162584

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Blood (2022) 140 (Supplement 1): 292–294.

https://doi.org/10.1182/blood-2022-159606

Published: 2022

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2021) 138 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2021-148423

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Hematobot: Retrieval‑augmented large language model‑based assistants for therapy, toxicity and frailty management in multiple myeloma by the spanish society of hematology and hemotherapy (SEHH)

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Multiple Myeloma Diagnosis and Monitoring

Myeloma and Lymphoma Medical Helpers: AI-Powered Decision Support Tools for Hematologic Malignancies

Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)

Epigenetic Profiling and Machine Learning for Enhanced Risk Stratification in Pediatric Acute Lymphoblastic Leukemia

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM)

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only